Showing results (21-30 of 226) with videos related to
Sort By:
Pageof 23
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 9, 2022
Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative studyMegan C Best, Nicci Bartley, Christine E Napier, et al.Journal of Medical Genetics|January 26, 2020
Cancer patients' views and understanding of genome sequencing: a qualitative studyNicci Bartley, Megan Best, Chris Jacobs, et al.BMC Medical Genetics|May 5, 2019
Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohortsRachel M Jones, Phillip E Melton, Mark Pinese, et al.Psycho-Oncology|April 23, 2026
Impact of Spiritual Wellbeing in Advanced Cancer Patients Receiving Genomic Test ResultsMegan C Best, Joseph Descallar, Grahame Simpson, et al.European Journal of Medical Genetics|April 29, 2022
Psychological predictors of cancer patients' and their relatives' attitudes towards the return of genomic sequencing resultsBettina Meiser, Phyllis Butow, Grace Davies, et al.The Journal of Biological Chemistry|January 29, 2008
Smad and p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular smooth muscleHarsha Dadlani, Mandy L Ballinger, Narin Osman, et al.Translational Oncology|May 26, 2020
Advanced Cancer Patient Knowledge of and Attitudes towards Tumor Molecular ProfilingGrace Davies, Phyllis Butow, Christine E Napier, et al.Plos One|July 30, 2013
High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohortGillian Mitchell, Mandy L Ballinger, Stephen Wong, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 1, 2017
Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPROGang Peng, Jasmina Bojadzieva, Mandy L Ballinger, et al.Future Oncology (London, England)|June 16, 2026
Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST programDerrick H W Siu, Frank P Y Lin, David M Thomas, et al.Pageof 23